- Home
- ALRS vs ZBIO Comparison
ALRS vs ZBIO Comparison
Compare ALRS & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALRS
- ZBIO
- Stock Information
- Founded
- ALRS 1879
- ZBIO 2019
- Country
- ALRS United States
- ZBIO United States
- Employees
- ALRS N/A
- ZBIO N/A
- Industry
- ALRS Major Banks
- ZBIO
- Sector
- ALRS Finance
- ZBIO
- Exchange
- ALRS Nasdaq
- ZBIO NYSE
- Market Cap
- ALRS 468.2M
- ZBIO 389.2M
- IPO Year
- ALRS 2019
- ZBIO 2024
- Fundamental
- Price
- ALRS $21.27
- ZBIO $9.05
- Analyst Decision
- ALRS Hold
- ZBIO Strong Buy
- Analyst Count
- ALRS 5
- ZBIO 7
- Target Price
- ALRS $23.20
- ZBIO $32.29
- AVG Volume (30 Days)
- ALRS 75.3K
- ZBIO 152.4K
- Earning Date
- ALRS 04-28-2025
- ZBIO 05-20-2025
- Dividend Yield
- ALRS 3.83%
- ZBIO N/A
- EPS Growth
- ALRS 118.02
- ZBIO N/A
- EPS
- ALRS 1.08
- ZBIO N/A
- Revenue
- ALRS $224,218,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- ALRS $36.47
- ZBIO N/A
- Revenue Next Year
- ALRS $4.64
- ZBIO N/A
- P/E Ratio
- ALRS $19.58
- ZBIO N/A
- Revenue Growth
- ALRS 35.73
- ZBIO N/A
- 52 Week Low
- ALRS $15.78
- ZBIO $5.83
- 52 Week High
- ALRS $24.41
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- ALRS 75.02
- ZBIO N/A
- Support Level
- ALRS $20.09
- ZBIO N/A
- Resistance Level
- ALRS $21.39
- ZBIO N/A
- Average True Range (ATR)
- ALRS 0.68
- ZBIO 0.00
- MACD
- ALRS 0.37
- ZBIO 0.00
- Stochastic Oscillator
- ALRS 97.49
- ZBIO 0.00
About ALRS Alerus Financial Corporation
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and Mortgage. It provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services as well as wealth management services, including financial & estate planning, trust, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.